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477Abstracts
SIONS: Patients starting a treatment with COXIBs +
GPAs are likely to have a previous history of GIDs sig-
niﬁcantly more severe and costly than patients who 
continue NSAIDs + GPAs. This constitutes a confound-
ing factor when assessing therapy effectiveness and safety,
in particular when evaluating co-prescription rates with
GPAs in patients treated with antinﬂammatories.
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OBJECTIVES: To focus on the Bulgarian market of M01
group for the period 1999–2001; the most consumptive
active principles (APs) within M01; to determine the
trend in M01 consumption and within. METHODS:
M01 consumption at national level has been calculated
by ATC/DDD methodology and expressed in
DDD/1000/day. Data have been collected from: a) the
import of wholesalers, b) the local industry sale reports
for the domestic market. Comparison has been made with
M01 consumption in Norway and Sweden (expressed 
in DDD/1000/day). RESULTS: M01 consumption at
national level has been calculated as follows: 1999—
14,216; 2000—13,764; and 2001—15,565. The most
consumptive APs within M01 were: Diclofenac (D)
1999—8,448; 2000—8,728; and 2001—9,753; Piroxi-
cam (P) 1999—3,380; 2000—2,892; and 2001—2,761;
Indometacin (Ind) 1999—1,457; 2000—1,061; and
2001—1,104; Ketoprofen (K) 1999—0,192; 2000—
0,439; and 2001—0,699; Tenoxicam (T) 1999—0,598;
2000—0,172; and 2001—0,699. Ibuprofen (Ib) con-
sumption was: 1999—0,169; 2000—0,030; and 2001—
0. The coxib Rofecoxib (R) consumption was registered
initially in 2001—0,054. CONCLUSIONS: M01 con-
sumption 1999–2001 did not show signiﬁcant variations.
The national demand for M01 is approximately 14
DDD/1000/day. M01 consumption in Norway and
Sweden was higher. D as the most consumptive AP at a
national level was about 67% of M01 consumption due
to 4 locally produced products. Dynamics within the
group was: D and K increased slightly; Ind showed rela-
tively steady-state position; P slightly decreased; the trend
in T consumption could not be deﬁned distinctly; Ib
decreased in consumption; Coxibs were with limited
place within M01. In comparison with Bulgaria, M01
consumption model in Norway and Sweden showed some
differences.
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OBJECTIVES: Osteoporosis, breast cancer and cardio-
vascular diseases are the main health problems among
postmenopausal women. We aimed to compare the cost-
effectiveness of raloxifene, alendronate or nasal calcitonin
in postmenopausal women, taking into account available
evidence for their preventive effect on a hip, vertebral,
wrist and ankle fractures, breast cancer, stroke and
myocardial infarction risk. METHODS: Markov model
was constructed to perform CEA and CUA over three
years from a health-care payers perspective, based on
Polish data on health-care resource utilisation and unit
cost. Treatment efﬁcacy and utility were derived from the
literature. Target population were patients aged 60–70,
without (group I) and with or without (group II) previ-
ous vertebral fracture. The outcomes measures were LYG
and QALYs gained, calculated on the basis of available
evidence for a preventive effect on an osteoporotic frac-
tures, breast cancer and cardiovascular events risk. The
cost-effectiveness threshold was calculated on basis of 1-
year haemodialysis treatment cost (60000 PLN, 1 USD =
4 PLN). The one-way and two-way sensitivity analysis
were performed. RESULTS: The highest effectiveness in
terms of LYG and QALYs was achieved with raloxifene
treatment, calcitonin was the least effective and the most
costly strategy. Incremental analysis suggests, that ralox-
ifene compared to alendronate was cost-effective: the
ICER was 15,975 PLN/LYG and 14,039 PLN/QALY
gained in group I, and 20,730 PLN/LYG and 17,915
PLN/QALY gained in group II. Sensitivity analyses
demonstrated robustness of the results in all cases calci-
tonin remained dominated strategy and ICER raloxifene
vs alendronian was below cost-effectiveness threshold.
CONCLUSIONS: Given the results of the analysis, in
osteoporotic postmenopausal women calcitonin is less
effective and more costly than alendronate and ralox-
ifene. Raloxifene can be considered as cost-effective when
compared with alendronate and within the Polish context
offers substantial beneﬁt at reasonable cost.
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